Free tool
FAERS Monitor: Xenpozyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761261 or its brand name (Xenpozyme, Olipudase Alfa-Rpcp). Reports on generic versions are filed under their own applications.
Reports
137
Serious
32
23% of reports
Hospitalization
21
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache10
- incorrect dose administered10
- weight increased10
- fatigue9
- nausea7
- off label use6
- vomiting6
- aspartate aminotransferase increased5
- condition aggravated5
- erythema5
- illness5
- pyrexia5
- sinusitis5
- weight decreased5
- alanine aminotransferase increased4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 39 |
| 2024 | 35 |
| 2025 | 29 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,022 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aspartate aminotransferase increasedSignal | 5 | 14.5 | 6.1 | 50 |
| alanine aminotransferase increasedSignal | 4 | 10.0 | 3.8 | 24 |
| sinusitisSignal | 5 | 7.5 | 3.2 | 22 |
| illnessSignal | 5 | 7.5 | 3.2 | 22 |
| weight increasedSignal | 10 | 6.9 | 3.8 | 45 |
| incorrect dose administeredSignal | 10 | 6.7 | 3.7 | 44 |
| erythemaSignal | 5 | 3.7 | 1.6 | 8 |
| weight decreasedSignal | 5 | 2.7 | 1.2 | 4 |
| condition aggravated | 5 | 2.5 | 1.1 | 3 |
| headacheSignal | 10 | 2.4 | 1.3 | 7 |
| pyrexia | 5 | 2.2 | 0.9 | 2 |
| vomiting | 6 | 2.0 | 0.9 | 2 |
| fatigue | 9 | 1.8 | 0.9 | 2 |
| nausea | 7 | 1.4 | 0.7 | 0 |
| off label use | 6 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.